These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 32747646)
1. Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score. Kaneko S; Kurosaki M; Joko K; Marusawa H; Kondo M; Kojima Y; Uchida Y; Kimura H; Tsuji K; Yagisawa H; Kusakabe A; Kobashi H; Akahane T; Tamaki N; Kirino S; Abe T; Yoshida H; Matsushita T; Hasebe C; Izumi N Sci Rep; 2020 Aug; 10(1):13021. PubMed ID: 32747646 [TBL] [Abstract][Full Text] [Related]
2. Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B. Kaneko S; Kurosaki M; Mashiba T; Marusawa H; Kondo M; Kojima Y; Uchida Y; Fujii H; Akahane T; Yagisawa H; Kusakabe A; Kobashi H; Abe T; Yoshida H; Ogawa C; Furuta K; Tamaki N; Tsuji K; Matsushita T; Izumi N; J Med Virol; 2023 Jan; 95(1):e28210. PubMed ID: 36222204 [TBL] [Abstract][Full Text] [Related]
3. Association of Serum Hepatitis B Virus RNA With Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Under Nucleos(t)ide Analogues Therapy. Liu S; Deng R; Zhou B; Liang X; Liu Z; Peng J; Chen J; Zhou Y; Guo Y; Chen Y; Li W; Shen S; Lu X; Zhao S; Liao X; Liang H; Lan Y; Hou J; Fan R; Sun J J Infect Dis; 2022 Sep; 226(5):881-890. PubMed ID: 34931674 [TBL] [Abstract][Full Text] [Related]
4. Nucleos(t)ide analogues associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients: a population-based cohort study. Wang JP; Kao FY; Wu CY; Hung YP; Chao Y; Chou YJ; Li CP Cancer; 2015 May; 121(9):1446-55. PubMed ID: 25537961 [TBL] [Abstract][Full Text] [Related]
5. Utility of Prediction Scores for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Treated with Nucleos(t)ide Analogues. Tawada A; Chiba T; Saito T; Ogasawara S; Suzuki E; Ooka Y; Arai M; Kanda T; Shinozaki M; Goto N; Nagashima K; Yokosuka O Oncology; 2016; 90(4):199-208. PubMed ID: 26934505 [TBL] [Abstract][Full Text] [Related]
6. Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma. Honda M; Shirasaki T; Terashima T; Kawaguchi K; Nakamura M; Oishi N; Wang X; Shimakami T; Okada H; Arai K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Kaneko S J Infect Dis; 2016 Apr; 213(7):1096-106. PubMed ID: 26621908 [TBL] [Abstract][Full Text] [Related]
7. Hepatitis B Virus Combo Mutations Improve the Prediction and Active Prophylaxis of Hepatocellular Carcinoma: A Clinic-Based Cohort Study. Yin J; Wang J; Pu R; Xin H; Li Z; Han X; Ding Y; Du Y; Liu W; Deng Y; Ji X; Wu M; Yu M; Zhang H; Wang H; Thompson TC; Ni W; Cao G Cancer Prev Res (Phila); 2015 Oct; 8(10):978-88. PubMed ID: 26290395 [TBL] [Abstract][Full Text] [Related]
8. Effects of antiviral therapy on long-term outcome after liver resection for hepatitis B virus-related hepatocellular carcinoma. Urata Y; Kubo S; Takemura S; Uenishi T; Kodai S; Shinkawa H; Sakae M; Kaneda K; Ohata K; Nozawa A; Suehiro S J Hepatobiliary Pancreat Sci; 2012 Nov; 19(6):685-96. PubMed ID: 22203455 [TBL] [Abstract][Full Text] [Related]
9. Entecavir and Low Genetic Barrier Antiviral Agents for Hepatocellular Carcinoma in Hepatitis B Viral Cirrhosis: Propensity Score Matching. Li T; Qu Y; Wang Y; Lin C; Yang B; Wang L J Coll Physicians Surg Pak; 2019 Apr; 29(4):317-323. PubMed ID: 30925952 [TBL] [Abstract][Full Text] [Related]
10. Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study. Kim MA; Kim SU; Sinn DH; Jang JW; Lim YS; Ahn SH; Shim JJ; Seo YS; Baek YH; Kim SG; Kim YS; Kim JH; Choe WH; Yim HJ; Lee HW; Kwon JH; Lee SW; Jang JY; Kim HY; Park Y; Kim GA; Yang H; Lee HA; Koh M; Lee YS; Kim M; Chang Y; Kim YJ; Yoon JH; Zoulim F; Lee JH Gut; 2020 Dec; 69(12):2214-2222. PubMed ID: 32209606 [TBL] [Abstract][Full Text] [Related]
11. Liver stiffness measurement at complete virological response in hepatoma prediction for HBV-related cirrhosis patient with potent antiviral agent. Wang JH; Hu TH; Chen CH; Hung CH; Yen YH; Chang KC; Lu SN Kaohsiung J Med Sci; 2019 Nov; 35(11):708-714. PubMed ID: 31430035 [TBL] [Abstract][Full Text] [Related]
12. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Chen CF; Lee WC; Yang HI; Chang HC; Jen CL; Iloeje UH; Su J; Hsiao CK; Wang LY; You SL; Lu SN; Chen CJ; Gastroenterology; 2011 Oct; 141(4):1240-8, 1248.e1-2. PubMed ID: 21703214 [TBL] [Abstract][Full Text] [Related]
13. Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues. Hosaka T; Suzuki F; Kobayashi M; Fujiyama S; Kawamura Y; Sezaki H; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H Aliment Pharmacol Ther; 2019 Feb; 49(4):457-471. PubMed ID: 30663078 [TBL] [Abstract][Full Text] [Related]
14. High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues. Shinkai N; Nojima M; Iio E; Matsunami K; Toyoda H; Murakami S; Inoue T; Ogawa S; Kumada T; Tanaka Y J Gastroenterol; 2018 Jul; 53(7):883-889. PubMed ID: 29288305 [TBL] [Abstract][Full Text] [Related]
15. The suppressive effect of nucleos(t)ide analogue treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients. Hiramatsu N; Yamada R; Takehara T J Gastroenterol Hepatol; 2016 Mar; 31(3):546-52. PubMed ID: 26574149 [TBL] [Abstract][Full Text] [Related]
16. Dynamic evaluation of hepatocellular carcinoma prediction models in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment. Kirino S; Tamaki N; Kurosaki M; Inada K; Yamashita K; Sekiguchi S; Hayakawa Y; Osawa L; Higuchi M; Takaura K; Maeyashiki C; Kaneko S; Yasui Y; Tsuchiya K; Nakanishi H; Itakura J; Takahashi Y; Izumi N J Viral Hepat; 2021 May; 28(5):787-794. PubMed ID: 33484033 [TBL] [Abstract][Full Text] [Related]
17. Current clinical evidence for nucleos(t)ide analogues in patients with HBV-related hepatocellular carcinoma. Yu Y; Ai J; Zhang W Expert Rev Gastroenterol Hepatol; 2017 Oct; 11(10):925-937. PubMed ID: 28661190 [TBL] [Abstract][Full Text] [Related]
18. Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen-Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study. Chang Y; Choe WH; Sinn DH; Lee JH; Ahn SH; Lee H; Shim JJ; Jun DW; Park SY; Nam JY; Cho EJ; Yu SJ; Lee DH; Lee JM; Kim YJ; Kwon SY; Paik SW; Yoon JH J Infect Dis; 2017 Dec; 216(11):1407-1414. PubMed ID: 29029102 [TBL] [Abstract][Full Text] [Related]
19. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Faria LC; Gigou M; Roque-Afonso AM; Sebagh M; Roche B; Fallot G; Ferrari TC; Guettier C; Dussaix E; Castaing D; Brechot C; Samuel D Gastroenterology; 2008 Jun; 134(7):1890-9; quiz 2155. PubMed ID: 18424269 [TBL] [Abstract][Full Text] [Related]
20. Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy. Cheung KS; Seto WK; Wong DK; Lai CL; Yuen MF J Viral Hepat; 2017 Aug; 24(8):654-661. PubMed ID: 28185363 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]